Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
This bill reauthorizes through 2031 federal grant programs for research and development of treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, including NIH grants for investigational drugs and FDA grants for therapy development. It establishes requirements for NIH to assess the safety and efficacy of investigational drugs and for grantees to report serious unexpected side effects. The bill also requires the FDA to publish a five-year action plan describing steps it will take to support development of safe and effective drugs for ALS and rare neurodegenerative diseases, and later report on actions taken under that plan. Rep. Mike Quigley (D-IL) sponsored the bill with 103 cosponsors from both parties.
What’s in the bill (3 sections)
- Sec. 2. Reauthorization of accelerating access to critical therapies
- Sec. 3. Improvements to program for grants for research on therapies
- Sec. 4. Fda rare neurodegenerative disease action plan
Where it is in the process
Community vote
How readers of ThePolitibase feel about this bill. Reader sentiment only — not a scientific poll, and not a measure of public opinion.
District map
Sponsor
Cosponsors (103)
Activity timeline
Jul 23
Jul 22
Jul 22
Jul 22
Jul 22
Jul 20
Jul 20
Jul 20
Jul 20
Jul 9
Full action log
All 103 cosponsors
In the news
One email when they vote against their own party. Nothing else.